Literature DB >> 22950637

Management of raised glucose, a clinical decision tool to reduce length of stay of patients with hyperglycaemia.

R Herring1, D L Russell-Jones, C Pengilley, H Hopkins, B Tuthill, J Wright, S V Hordern, S Davidson.   

Abstract

OBJECTIVE: To assess whether the introduction of a management of raised glucose clinical decision tool could improve assessment of patients with hyperglycaemia by non-specialist physicians, leading to early discharge and improved quality of inpatient care.
METHODS: Participants were adults aged 18 years or over presenting to the Medical Assessment Unit with a capillary blood glucose level > 11.1 mmol/l. Phase 1 of the study (phase 1) evaluated current clinical practice and potential impact of the clinical decision tool. Phase 2 evaluated the effectiveness of the management of raised glucose tool in clinical practice. Primary outcome measures were inpatient length of stay and same-calendar-day discharges. Secondary outcome measures were diabetes specialist input, patient assessment, intravenous insulin infusion use and patient satisfaction.
RESULTS: Implementation of the management of raised glucose clinical decision tool allowed safe, same-calendar-day discharges of 40% of patients with hyperglycaemia as their primary reason for attendance. Median length of stay was lower in the phase 1 than in phase 2 (1.0 vs. 3.5 days, P < 0.01). Early discharge did not result in an increase in readmissions. There was improvement in hyperglycaemia assessment for all patients (P < 0.01), a reduction in the use of intravenous insulin infusions (P < 0.01) and high level of patient satisfaction.
CONCLUSION: The management of raised glucose clinical decision tool resulted in a significant increase in the number of same-calendar-day discharges and reduction in hospital length of stay without adverse impact on readmission rates. Additionally, the tool was associated with improvements in inpatient diabetes care and patient satisfaction.
© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22950637     DOI: 10.1111/dme.12006

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  1 in total

Review 1.  Cost and economic benefit of clinical decision support systems for cardiovascular disease prevention: a community guide systematic review.

Authors:  Verughese Jacob; Anilkrishna B Thota; Sajal K Chattopadhyay; Gibril J Njie; Krista K Proia; David P Hopkins; Murray N Ross; Nicolaas P Pronk; John M Clymer
Journal:  J Am Med Inform Assoc       Date:  2017-05-01       Impact factor: 4.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.